Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat-CTEPH: Effect on Peak Cardiac Index after BPA-normalized Hemodynamics
jRCTs041200052Completed
- Sponsor
- Bayer
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Riociguat continuation with Placebo (2 arms). Primary endpoint: Change in Peak CI during CPET from baseline to 16 weeks. Started Jun 2021; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCTs041200052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200052.